Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 480,370 | 492,608 | 398,837 | 365,306 | 254,061 |
| Depreciation Amortization | 314,124 | 303,870 | 265,540 | 234,924 | 198,095 |
| Income taxes - deferred | -50,903 | -35,884 | -24,006 | -133 | -21,895 |
| Accounts receivable | -33,434 | -150,570 | -26,633 | -85,627 | -8,323 |
| Accounts payable and accrued liabilities | -20,427 | -2,652 | 44,901 | 748 | 29,775 |
| Other Working Capital | -102,380 | -152,554 | 42,942 | -26,275 | 6,179 |
| Other Operating Activity | 96,548 | 164,822 | 59,218 | 57,632 | 23,044 |
| Operating Cash Flow | $683,898 | $619,640 | $760,799 | $546,575 | $480,936 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -54,215 | -158,274 | -45,555 | -26,692 | -22,341 |
| PPE Investments | -318,528 | -324,733 | -228,772 | -166,560 | -140,514 |
| Net Acquisitions | -194,785 | -120,117 | -1,170,401 | -418,628 | -515,701 |
| Sale Of Investment | 6,667 | 4,549 | 6,532 | 11,401 | 942 |
| Other Investing Activity | -2,294 | -9,347 | 264 | -1,065 | -3,888 |
| Investing Cash Flow | $-563,155 | $-607,922 | $-1,437,932 | $-601,544 | $-681,502 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 776,353 | 2,952,430 | 6,951,113 | 2,230,988 | 3,358,461 |
| Debt Repayment | -851,676 | -2,932,636 | -6,281,132 | -2,200,400 | -3,131,181 |
| Common Stock Issued | 25,597 | 25,110 | 45,652 | 46,586 | 34,546 |
| Common Stock Repurchased | -24,155 | -38,651 | -40,707 | -23,979 | -18,087 |
| Other Financing Activity | -11,640 | -48,650 | -2,328 | -5,947 | -11,802 |
| Financing Cash Flow | $-85,521 | $-42,397 | $672,598 | $47,248 | $231,937 |
| Exchange Rate Effect | 8,044 | 25,579 | 17,730 | 794 | 11,357 |
| Beginning Cash Position | 241,214 | 246,314 | 233,119 | 240,046 | 197,318 |
| End Cash Position | 284,480 | 241,214 | 246,314 | 233,119 | 240,046 |
| Net Cash Flow | $43,266 | $-5,100 | $13,195 | $-6,927 | $42,728 |
| Free Cash Flow | |||||
| Operating Cash Flow | 683,898 | 619,640 | 760,799 | 546,575 | 480,936 |
| Capital Expenditure | -318,528 | -324,733 | -228,772 | -166,560 | -140,514 |
| Free Cash Flow | 365,370 | 294,907 | 532,027 | 380,015 | 340,422 |